Why Alector, Inc.’s (ALEC) Stock Is Down 8.66%
As of Tuesday, October 13, Alector, Inc.’s ALEC share price has dipped by 8.66%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer’s disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson’s disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Alector, Inc.’s (ALEC) Stock Is Down 11.06%
As of Tuesday, October 13, Alector, Inc.’s ALEC share price has dipped by 11.06%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Alector, Inc.’s (ALEC) Stock Is Up 5.07%
As of Tuesday, October 06, Alector, Inc.’s ALEC share price has surged by 5.07%, which has investors questioning if this is right time to sell.Michael Rose
Why Alector, Inc.’s (ALEC) Stock Is Up 32.32%
As of Monday, October 05, Alector, Inc.’s ALEC share price has surged by 32.32%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Alector, Inc.’s (ALEC) Stock Is Up 22.54%
As of Monday, October 05, Alector, Inc.’s ALEC share price has surged by 22.54%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | ALEC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $232.2 | $237.5 | 29% |
|
| Shares Out (Mil) | 111.2 | 53.9 | 64% |
|
| Institutional Ownership | 92.2% | 93.1% | 61% |
|
| Float (Mil) | 84.9 | 41.4 | 57% |
|
| Beta | 0.65 | 0.95 | 38% |
|
| Avg Daily Volume (000s) | 11,903 | 628 | 97% |
|
| Price Change (52-week) |
(33.8%) | 49.0% | 27% |
|
| Growth | ALEC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (0.1%) | 12.4% | 17% |
|
| Net Income (5yr) | 5.6% | (10.2%) | 48% |
|
| EPS (5yr) | 10.7% | 15.7% | 48 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 21.3% | (15.7%) | 80% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.210) | ($0.693) | ($0.732) | |
| Month Ago EPS | ($0.228) | ($0.863) | ($0.746) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.227) | ($0.883) | ($0.700) | |
| Year/Year Chg | 1.4% | (50.1%) | (46.8%) | |
| Financials | ALEC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $14 | $37 | 11% |
|
| Net Income (TTM) (Mil) | ($118) | ($44) | 10% |
|
| EPS (TTM) | ($1.086) | ($1.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($158) | ($33) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $15 | $2 | 60% |
|
| Long-Term Debt (Q1) (Mil) | $14 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $78 | $174 | 19% |
|
| Valuation | ALEC | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.27 | na |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ALEC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (615.1%) | 66.9% | 0% |
|
| Net Margin | (850.1%) | (75.3%) | 0% |
|
| ROA | (42.1%) | (47.7%) | 13% |
|
| ROE | (385.1%) | (55.0%) | 2% |
|
| Liabilities to Assets | 104.9% | 29.4% | 95% |
|
| F-Score | 2 | 2 | 7% |
|
Passing Stock Screens
As of 10/12/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.3% |
| +/- S&P 500: | +13.8 |
